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Local anesthetic toxicity is an uncommon but well-
documented complication of regional anesthesia. The 
mechanism of local anesthetic toxicity from a peripheral nerve 
block can be due to either a direct intravascular injection or 
from systemic absorption of a toxic dose of local anesthetics.
We report two cases of local anesthetic toxicity, including 
central nervous system toxicity without any cardiac toxicity, 
following accidental overdose of ropivacaine for infraclavicular 
block.
The first patient was a 36-year-old female (ASA I, 52 kg, 
and 160 cm), who presented for surgery of the right forearm 
under infraclavicular block. There was no medical history of 
neurological or cardiac disease. Physical examination and 
electrocardiogram (ECG) were unremarkable. 
The patient did not receive any sedatives before surgery. 
In the operating room, standard monitoring (pulse oximetry, 
noninvasive blood pressure cuff, and ECG) was applied. Using 
an insulated needle (Stimuplex
Ⓡ A, B. Braun, Germany) and 
a nerve stimulator (Stimuplex
Ⓡ HNS 12, B. Braun, Germany), 
a vertical infraclavicular block was performed to provide 
anesthesia [1]. Once an ulnar nerve response with a current of 
0.5 mA was obtained, a total dose of 40 ml of 0.75% ropivacaine 
(300 mg; 5.77 mg/kg) without epinephrine was slowly 
injected with negative aspiration in 5 ml increments. Verbal 
communication was made during injection, and no early signs 
of systemic toxicity were noted. Ten minutes after the injection, 
sensory block was complete in the right arm. About twenty 
minutes after the injection, complete motor block was achieved 
in the radial, median, ulnar, and musculocutaneous nerves.
Twenty-four minutes after the injection, the patient 
complained of numbness in the tongue, nausea, and dizziness. 
During this time, her blood pressure, heart rate, and oxygen 
saturation was 156/102 mmHg, 81 beats/min, and 98%, 
respectively. No changes were observed on the ECG. Suspecting 
ropivacaine-induced toxicity, 50 mg of thiopental sodium was 
administered for seizure prophylaxis, and supplemental oxygen 
was given via face mask. She recovered over 10 minutes. The 
patient had no awareness of the incident and was informed. The 
decision was made to perform surgery and further sedation was 
given with continuous infusion of propofol. The patient made 
an uneventful postoperative recovery. 
The second patient was a 60-year-old female (ASA I, 47 kg, 
and 142 cm) who was scheduled for surgery of the right forearm 
under infraclavicular block. She was in good general health, 
with no significant past medical history and in particular, 
no history of convulsions or epilepsy. She was taking no 
medications and had no allergies. 
No sedation was used for the block placement. A vertical 
infraclavicular block was performed with the same technique 
as described in Case 1. At the first attempt, blood was obtained, 
and the needle was withdrawn. After shifting of the puncture 
site in a 1 cm lateral direction, an ulnar nerve response of 
fingers with a current of 0.5 mA was obtained and a total dose 
of 40 ml of 0.75% ropivacaine (300 mg; 6.38 mg/kg) without 
epinephrine was slowly injected in 5 ml increments with gentle 
aspirations between doses. No spontaneous blood return was 
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seen, and no blood could be aspirated. Verbal contact was 
maintained during the performance of the block. Successful 
motor and sensory block of the upper limb occurred within 5 
min of the injection.
Twenty-eight minutes after the injection, the patient 
became disoriented and drowsy. Immediately thereafter, she 
developed tonic-clonic seizure activity. Supplemental oxygen 
was immediately given via face mask. Propofol 40 mg was 
administered, resulting in termination of the seizure. During 
this time, her blood pressure, heart rate, and oxygen saturation 
was 151/88 mmHg, 66 beats/min, and 100%, respectively. No 
arrhythmias were seen on the ECG. Fifteen minutes later, the 
patient regained consciousness, had no recall of the preceding 
events, had no sequelae, and was informed. As the patient 
remained clinically stable and her mental status had returned to 
baseline, a decision was made to proceed with surgery, which 
was uneventful.
A peripheral nerve block, such as brachial plexus block, 
generally requires the use of relatively high doses of local 
anesthetics. Ropivacaine is an amide local anesthetic with a 
long duration of action providing increased safety as compared 
to racemic bupivacaine, because of the reduced potential for 
cardiovascular and central nervous system toxicity. The lower 
toxicity of ropivacaine may be advantageous for brachial plexus 
blocks, enabling large doses to be used. Subsequently, brachial 
plexus block induced by doses up to 40 ml of 0.75% ropivacaine 
(300 mg) provided excellent anesthesia without local anesthetic 
toxicity [2]. 
The maximum recommended dose of ropivacaine for 
brachial plexus block in Finland and the United States is 300 
mg [3]. However, standard doses can not be applied to every 
patient. 
In our cases, 300 mg (Case 1, 5.77 mg/kg; Case 2, 6.38 mg/
kg) of ropivacaine was used for infraclavicualr block, and local 
anesthetic toxicities occurred after 24 and 28 min, respectively. 
Plasma ropivacaine levels were, unfortunately, not measured 
in the cases presented here. However, the delayed onset of 
the symptoms and complete brachial plexus block suggest a 
nonintravascular injection, indicating rapid absorption of a 
large dose of ropivacaine. Therefore, 300 mg of ropivacaine 
may have been excessive in these patients, although the same 
amount was used uneventfully in a previous study [2]. Several 
previous studies have reported [4,5] that 300 mg of ropivacaine 
could produce local anesthetic toxicity limited to the central 
nervous system. A review by Rosenberg et al. [3] suggested that 
because current recommendations regarding maximum doses 
of local anesthetics are not evidence based, the dose of local 
anesthetics should be block-specific, site-specific, and patient-
specific.
In summary, we have presented 2 cases of local anesthetic 
toxicity induced by high doses (300 mg) of ropivacaine. It is 
difficult to recommend a safe maximum dose of ropivacaine, 
but dose calculations must be made on an individual basis, 
taking into account the sex, weight, and physical status of the 
patient.
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